References
- 1. Cancer in Slovenia 2009. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2013.
- 2. Buyukasik O, Hasdemir AO, Gulnerman Y, Col C, Ikiz O. Second primary cancers in patients with gastric cancer. Radiol Oncol 2010; 44: 239-43.
- 3. Rajev L. Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol 2010; 11: 14-23.
- 4. Buergy D, Lohn F, Baack T, Siebenlist K, Haneder S, Michaely H, et al. Radiotherapy for tumors of the stomach and gastoesophageal junction - a review of its role in multimodal therapy. Radiat Oncol 2012; 7: 192.
- 5. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.
- 6. Oblak I, Velenik V, Anderluh F, Strojan P. Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia. Eur J Surg Oncol 2007; 33: 982-7.
- 7. Oblak I, Anderluh F, Velenik V. Postoperative radiochemotherapy for gastric adenocarcinoma: long term results. Radiol Oncol 2009; 43: 274-81.
- 8. Rossi D, Alessandroni P, Catalano V, Giordani P, Fedeli A, Baldelli AM, et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin Breast Cancer 2007; 7: 857-60.
- 9. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27: 23-44.
- 10. Ocvirk J, Rebersek M, Skof E, Hlebanja Z, Boc M. Randomized prospective phase II study to compare the combination chemotherapy regiment epirubicin, cisplatin and 5-fluorouracil with epirubicin, cisplatin and capecitabine in patients with advanced or metastatic gastric cancer. Am J Clin Oncol 2012; 35: 237-41.
- 11. Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wrong A, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012; 23: 1190-7.
- 12. American Joint Committee on Cancer. AJCC cancer staging manual. 7th edition. New York: Springer-Verlag; 2009.
- 13. Ajani JA, Welch SR, Raber MN, Fiels WS, Krakoff IM. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59.
- 14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
- 15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
- 16. Cox DR. Regression models and life-tables. J R Stat Soc Bull 1972; 34: 187-220.
- 17. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. Ca Cancer J Clin 2000; 50: 7-33.
- 18. Ajani JA. Chemotherapy for gastric carcinoma: new and old options. Oncology (Huntingt) 1998; 12 (10 Suppl 7): 44-7.
- 19. Gunderson LL. Gastric cancer: patterns of relapse after surgical resection. Semin Radiat Oncol 2002; 12: 150-61.
- 20. Park SH, Kim DY, Heo JS, Lim DH, Park CK, Lee KW, et al. Postoperative chemotherapy for gastric cancer. Ann Oncol 2003; 14: 1373-7.
- 21. Kim S, Lim DH, Lee J, Kang WK, McDonald JS, Park CH, et al. An observation study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-85.
- 22. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani Ja, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-33.
- 23. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010; 28: 2430-6.
- 24. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-73.
- 25. Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012; 104: 361-6.
- 26. Yu C, Yu R, Zhu W, Song Y, Li T. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol 2012; 138: 255-9.
- 27. Jansen EP, Boot H, Saunders MP, Crosby TD, Dubbelman R, Bartelink H, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 2007; 69: 1424-8.
- 28. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer 1998; 1: 125-33.
- 29. Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E, et al. Adjuvant chemotherapy in patients with stage III or IV radically resected gastric cancer. Arch Surg 2010; 145: 233-8.
- 30. Yao JC, Mansfield PF, Pisters PWT, Feig BW, Janjan NA, Crane C, et al. Combined modality therapy for gastric cancer. Semin Surg Oncol 2003; 21: 223-7.
- 31. Avital I, Pisters PWT, Kelsen DP, Willett CG. Cancer of the stomach. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer; principles & practice of oncology. 9th edition. Philadelphia: Lippincott-Williams &Wilkins; 2004. p. 924-54.
- 32. Willett CG, Gunderson LL. Stomach. In: Halperin EC, Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 5th edition. Philadelphia: Lippincott-Williams &Wilkins; 2008. p. 1318-35.
- 33. Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol 2007; 14: 2687-90.
- 34. Ikeguchi M, Kaibara N. Lymph node metastasis at the splenic hilum in proximal gastric cancer. Am Surg 2004; 70: 645-8.
- 35. Huang CM, Wang JB, Lu HS, Zheng CH, Li P, Wie JW, et al. Prognostic impact of splenectomy on advanced proximal gastric cancer with No.10 lymph node metastasis. Chin Medl J 2009; 122: 2757-62.